Overview of Incidence and Management of CRS Observed With Teclistamab in the MajesTEC-1 Study of Patients With Relapsed/Refractory Multiple Myeloma

Experts Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, provide a broad overview of cytokine release syndrome as it relates to the management of multiple myeloma.

Key opinion leaders share comprehensive insight to the treatment armamentarium for patients with relapsed/refractory multiple myeloma.

Experts on multiple myeloma discuss how to select treatment options in later lines of therapy.

Focused discussion on the advent of cytokine release syndrome in MajesTEC-1 and how it compared to the benefits derived from teclistamab therapy.

Key opinion leaders Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, reflect on the use of tocilizumab in patients experiencing cytokine release syndrome on MajesTEC-1.

Following their review of data from MajesTEC-1, panelists consider how they manage patients with cytokine release syndrome in the real-world setting.

Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, share closing thoughts on the evolving landscape of cytokine release syndrome management in relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.